Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Transporter Substrate/Inhibition Screening Assay Service
Are you currently facing challenges with unpredictable human pharmacokinetics, potential drug-drug interactions, or the limitations of rodent models in your preclinical studies? Creative Biolabs helps you to enhance the predictability of drug behavior in humans and de-risk your drug candidates through advanced in vitro non-human primate (NHP) transporter assays. Our high-fidelity approach provides a clearer path to a successful clinical trial, saving you valuable time and resources.
Overview of Our Assays
What Our Service Is
Our NHP transporter substrate/inhibition screening services are a critical part of the drug development process. These in vitro assays assess how your drug candidate interacts with drug transporters, which are specialized proteins that regulate a drug's movement into and out of cells. By understanding these interactions, we can help predict how the drug will be absorbed, distributed, metabolized, and excreted in the body.
This service is essential for:
- Predicting Potential Drug-Drug Interactions (DDIs): Identifying if your drug will inhibit transporters, which could alter the concentration and toxicity of other co-administered medications.
- Investigating Transport Mechanisms: Determining if your drug is a substrate for specific uptake or efflux transporters.
- Optimizing Dosing Strategies: Guiding the selection of appropriate doses and patient populations for clinical trials.
Why Choose Us?
Choosing Creative Biolabs means gaining a significant advantage in the unpredictable landscape of drug development. The primary pain point for many researchers is the poor translational correlation between preclinical models, like rodents, and human outcomes. This can lead to costly late-stage failures.
Our value proposition is centered on enhanced predictability. By leveraging NHP models, which share closer genetic and physiological similarities with humans, we provide data that more accurately reflects human pharmacokinetics. This enhanced predictability helps you to de-risk your drug candidate early, identify potential safety issues, and design more effective clinical trials, ultimately saving you time and money.
Diagram illustrating the transport mechanism and kinetics of a chimpanzee less-characterized transporter.
Key Benefits of Our Service
The use of NHP models for transporter screening offers unparalleled benefits for your drug development program. Our approach leverages the close genetic and physiological similarities between NHPs and humans, particularly in the expression and function of drug transporters, to provide highly predictive data.
- Enhanced Predictability: Unlike rodent models where transporter activity can vary significantly from humans, NHPs offer a more accurate representation of human pharmacokinetics. Our services provide a higher degree of confidence in predicting drug behavior, including its ability to cross key biological barriers like the blood-brain barrier. Published data shows that NHP models are superior for evaluating efflux transporter activity, providing critical insights into brain penetration.
- Expert Customization: Every drug candidate is unique. Our team of experts works closely with you to design a customized assay panel that specifically addresses the needs of your project, including the selection of relevant transporters and study parameters.
- Comprehensive Reporting: We provide in-depth reports that include not only the raw data but also a detailed analysis and expert interpretation. Our reports help you understand the implications of the data and guide your next steps in the development process.
- Responsive Support: We pride ourselves on rapid response times and open communication throughout your project. Our team is available to answer your questions and provide support, ensuring a seamless experience from start to finish.
How Creative Biolabs' Assays Can Assist Your Project?
Our services provide a clear, actionable path to understanding your drug candidate's interactions with drug transporters, ensuring you have the data needed to make informed decisions. We offer a comprehensive and transparent workflow designed to deliver the most relevant and predictive data possible.
Workflow
01
Required Starting Materials
02
Project Initiation and Assay Design
03
Cell Culture and Transporter Expression
04
Substrate/Inhibition Screening
05
Data Acquisition and Analysis
06
Report Generation and Interpretation
Key Deliverables
Upon completion of the project, Creative Biolabs provides a comprehensive package of deliverables to support your regulatory submissions and project decisions:
- Final Report: A detailed PDF report including study objectives, methodology, results, and expert conclusions.
- Raw Data Files: Complete raw data in a format suitable for your internal analysis.
- Tabulated Data: A summary of key results, including IC50 values for inhibition studies and Vmax/Km values for substrate studies.
- Model Annotations: A description of the cell lines and transporters used in the assay.
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 compounds
- Typical Turnaround Time (TAT): 10-15 business days
- Assay Pass Rate: >98%
Our Valued Partners
Frequently Asked Questions
Q: Why should I use NHP models for transporter assays instead of a more common and less expensive rodent model?
A: While rodent models are useful, there are often significant species differences in transporter expression and function that can lead to misleading data. NHPs are a more reliable model for predicting human pharmacokinetics, particularly for complex processes like drug brain penetration. Using an NHP model can provide more translatable data, helping you to de-risk your program and avoid costly failures later in the development process.
Q: My drug is intended for a target outside the central nervous system. Do I still need to screen for interactions with efflux transporters like P-gp and BCRP?
A: Absolutely. P-gp and BCRP are found in many tissues beyond the blood-brain barrier, including the gut, liver, and kidneys. Interactions with these transporters can affect a drug's absorption and elimination from the body, leading to potential safety and efficacy issues. Our comprehensive panel helps you understand these interactions wherever they may occur.
Q: How do you ensure the data from your in vitro assays is truly predictive of in vivo human behavior?
A: Our assays are carefully designed to closely mimic physiological conditions. We use cell lines that overexpress specific human and NHP transporters, and we follow rigorous quality control procedures. The data we generate is used to calculate key parameters (e.g., IC50 values) that are then used to predict potential in vivo outcomes, guiding your drug development with a high degree of confidence.
Q: We have a tight development timeline. What is your typical turnaround time for these studies?
A: We understand that speed is critical in drug development. Our streamlined process and dedicated NHP resources allow us to provide a fast turnaround without compromising on data quality. The typical timeframe for our studies is 4-8 weeks, and we are happy to discuss your specific needs to ensure we can meet your project deadlines.
Q: I'm new to drug development and unsure which transporter assays are most relevant for my compound. Can you help me?
A: We'd love to! Our team of experts has decades of experience in DMPK and can provide guidance on the most relevant transporter assays for your specific project. We will work with you to design a custom study that is both scientifically sound and cost-effective. Please don't hesitate to reach out for a consultation.
Contact Us
At Creative Biolabs, we are committed to delivering superior preclinical services that expedite the drug development process. Our screening assays for NHP transporter substrates/inhibition serve as an effective means to mitigate risks, anticipate possible drug-drug interactions, and boost the probability of clinical success. We welcome the opportunity to be your innovation partner. Reach out to our team for further details and to discuss your project.
Reference
- Yee, Sook Wah, et al. "Illuminating the function of the orphan transporter, SLC22A10, in humans and other primates." Nature communications 15.1 (2024). Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1038/s41467-024-48569-7